ストックスクリーナーアプリを入手
2.80
0.36%
-0.01
前日終値:
$2.81
開ける：
$2.848
24時間の取引高:
14,687
Relative Volume:
0.81
時価総額：
$28.43M
収益：
-
当期純損益:
$-23.87M
株価収益率:
-0.1423
EPS:
-19.67
ネットキャッシュフロー:
$-47.63M
1週間 パフォーマンス:
+2.00%
1か月 パフォーマンス:
+1.82%
6か月 パフォーマンス:
-21.02%
1年 パフォーマンス:
-39.85%
1日の値動き範囲:
$2.78
$2.848
1週間の範囲:
$2.6804
$3.28
52週間の値動き範囲:
$2.30
$4.67
Polypid Ltd Stock (PYPD) Company Profile
PYPD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
2.79 | 29.04M | 0 | -23.87M | -47.63M | -19.67 |
|
ONC
Beigene Ltd Adr
|
240.49 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.58 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.73 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.59 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2021-09-14 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-07-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 開始されました | Alliance Global Partners | Buy |
| 2020-07-21 | 開始されました | BMO Capital Markets | Outperform |
| 2020-07-21 | 開始されました | Barclays | Overweight |
| 2020-07-21 | 開始されました | Raymond James | Outperform |
すべてを表示
Polypid Ltd (PYPD) 最新ニュース
PolyPid chairman to step down at June shareholder meeting By Investing.com - Investing.com Nigeria
PolyPid chairman to step down at June shareholder meeting - Investing.com Australia
PolyPid Announces Leadership Changes Ahead of June 2025 Shareholder Meeting - TipRanks
PolyPid Opens Virtual Access to Investors: Key Presentation and 1-on-1 Meetings at Lytham Conference - Stock Titan
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - GlobeNewswire
Head to Head Survey: PolyPid (NASDAQ:PYPD) & Lombard Medical (OTCMKTS:EVARF) - Defense World
Tenon Medical (NASDAQ:TNON) vs. PolyPid (NASDAQ:PYPD) Critical Comparison - Defense World
PolyPid Ltd. Earnings Call: Progress and Challenges - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call Transcript - Insider Monkey
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
PolyPid Ltd. Reports Q1 2025 Results and Trial Progress - TipRanks
Polypid Q1 Net Income USD -8.3 Million - marketscreener.com
PolyPid (PYPD) Prepares for Transformational 2025 with Promising - GuruFocus
PolyPid Completes Enrollment in Phase 3 Trial of D-PLEX100 - TipRanks
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Transcript : PolyPid Ltd., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PolyPid (PYPD) Expected to Announce Earnings on Wednesday - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - Defense World
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewswire
PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan
Reviewing Baxter International (NYSE:BAX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire
PolyPid to Reveal Next-Gen Surgical Innovation Pipeline at Elite Citizens Life Sciences Conference - Stock Titan
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 25.9% - Defense World
What is HC Wainwright’s Estimate for PolyPid Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for PolyPid Q1 Earnings? - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target - Investing.com Australia
PolyPid’s (PYPD) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target By Investing.com - Investing.com Canada
PolyPid stock touches 52-week low at $2.32 amid market challenges By Investing.com - Investing.com South Africa
PolyPid stock touches 52-week low at $2.32 amid market challenges - Investing.com Australia
Surgical Site Infections Clinical and Non-Clinical Studies, - openPR.com
Barclays Reaffirms Their Hold Rating on PolyPid (PYPD) - The Globe and Mail
Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - Yahoo
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
Polypid Ltd (PYPD) 財務データ
収益
当期純利益
現金流量
EPS
12.23%
大文字化:
|
ボリューム (24 時間):